Heterogeneity Amongst GLP-1 RA Cardiovascular Outcome Trials Results: Can Definition of Established Cardiovascular Disease Be the Missing Link?

Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that reduce b...

ver descrição completa

Detalhes bibliográficos
Autor principal: Melo, M (author)
Outros Autores: Gavina, C (author), Silva-Nunes, J (author), Andrade, L (author), Carvalho, D (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
HCC END
Antidiabetic Drug
GLP-1 RA
Cardiovascular Disease
Cardiovascular Outcome Trials
Type 2 Diabetes
Texto completo:http://hdl.handle.net/10400.17/3779
País:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/3779

Texto Completo

http://hdl.handle.net/10400.17/3779

Registros relacionados